Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Farmers Insurance
Deloitte
Chinese Patent Office
Merck
Express Scripts
McKesson
Cerilliant
McKinsey

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,481,598

« Back to Dashboard

Which drugs does patent 8,481,598 protect, and when does it expire?

Patent 8,481,598 protects FETZIMA and is included in one NDA.

This patent has eight patent family members in four countries.
Summary for Patent: 8,481,598
Title:Stable dosage forms of levomilnacipran
Abstract: The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.
Inventor(s): Surana; Rahul (Commack, NY), Divi; Murali (Ronkonkoma, NY), Chhettry; Anil (Holtsville, NY)
Assignee:
Application Number:13/006,993
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,481,598

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-001 Jul 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-002 Jul 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-003 Jul 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-004 Jul 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,481,598

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,865,937 Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide ➤ Sign Up
9,259,403 Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Daiichi Sankyo
McKinsey
Covington
Fuji
Fish and Richardson
McKesson
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.